Hiroki Kushiya

Dr. Hiroki Kushiya

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 November 2022 in Cancers
Verified
Journal Article
Open access
PDF file
HKHiroki Kushiya
Hiroki Kushiya
KHKei Hiraoka
Kei Hiraoka
TSTomohiro Suzuki
Tomohiro Suzuki
KIKazuho Inoko
Kazuho Inoko
AIAkihito Inagaki
Akihito Inagaki
SHSatoshi Hirano
Satoshi Hirano
Therapeutic efficacy of retroviral replicating vector (RRV)-mediated prodrug activator gene therapy has been demonstrated in a variety of tumor models, but clinical investigation of this approach has so far been restricted to glioma and gastrointestinal malignancies. In the present study, we evaluated replication kinetics, transduction efficiency, and therapeutic efficacy of RRV in experimental models of lung cancer. RRV delivering GFP as a reporter gene showed rapid viral replication in a panel of lung cancer cells in vitro, as well as robust intratumoral replication and high levels of tumor transduction in subcutaneous and orthotopic pleural dissemination models of lung cancer in vivo. Toca 511 (vocimagene amiretrorepvec), a clinical-stage RRV encoding optimized yeast cytosine deaminase (yCD) which converts the prodrug 5-fluorocytosine (5-FC) to the active drug 5-fluorouracil (5-FU), showed potent cytotoxicity in lung cancer cells upon exposure to 5-FC prodrug. In vivo, Toca 511 achieved significant tumor growth inhibition following 5-FC treatment in subcutaneous and orthotopic pleural dissemination models of lung cancer in both immunodeficient and immunocompetent hosts, resulting in significantly increased overall survival. This study demonstrates that RRV can serve as highly efficient vehicles for gene delivery to lung cancer, and indicates the translational potential of RRV-mediated prodrug activator gene therapy with Toca 511/5-FC as a novel therapeutic strategy for pulmonary malignancies.

27 February 2019 in Asian Journal of Endoscopic Surgery
Verified
Journal Article
Closed access
PDF file
HKHiroki Kushiya
Hiroki Kushiya
YEYuma Ebihara
Yuma Ebihara
YNYoshitsugu Nakanishi
Yoshitsugu Nakanishi
TAToshimichi Asano
Toshimichi Asano
TNTakehiro Noji
Takehiro Noji
SHSatoshi Hirano
Satoshi Hirano

1 July 2022 in Preprints.org
Verified
Preprint
Open access
PDF file
HKHiroki Kushiya
Hiroki Kushiya
KHKei Hiraoka
Kei Hiraoka
TSTomohiro Suzuki
Tomohiro Suzuki
KIKazuho Inoko
Kazuho Inoko
AIAkihito Inagaki
Akihito Inagaki
SHSatoshi Hirano
Satoshi Hirano
Therapeutic efficacy of retroviral replicating vector (RRV)-mediated prodrug activator gene therapy has been demonstrated in a variety of tumor models, but clinical investigation of this approach has so far been restricted to glioma and gastrointestinal malignancies. In the present study, we evaluated replication kinetics, transduction efficiency, and therapeutic efficacy of RRV in experimental models of lung cancer. RRV delivering GFP as a reporter gene showed rapid viral replication in a panel of lung cancer cells in vitro, as well as robust intratumoral replication and high levels of tumor transduction in subcutaneous and orthotopic pleural dissemination models of lung cancer in vivo. Toca 511 (vocimagene amiretrorepvec), a clinical-stage RRV encoding optimized yeast cytosine deaminase (yCD) which converts the prodrug 5-fluorocytosine (5-FC) to the active drug 5-fluorouracil (5-FU), showed potent cytotoxicity in lung cancer cells upon exposure to 5-FC prodrug. In vivo, Toca 511 achieved significant tumor growth inhibition following 5-FC treatment in subcutaneous and orthotopic pleural dissemination models of lung cancer in both immunodeficient and immunocompetent hosts, resulting in significantly increased overall survival. This study demonstrates that RRV can serve as highly efficient vehicles for gene delivery to lung cancer, and indicates the translational potential of RRV-mediated prodrug activator gene therapy with Toca 511/5-FC as a novel therapeutic strategy for pulmonary malignancies.

1 August 2025 in Medicine
Verified
Journal Article
Open access
YIYuki Itagaki
Yuki Itagaki
SSShoki Sato
Shoki Sato
YOYuko Omori
Yuko Omori
HYHiroyuki Yamamoto
Hiroyuki Yamamoto
KKKotaro Kimura
Kotaro Kimura
SHSatoshi Hirano
Satoshi Hirano
Rationale: Intraductal papillary mucinous neoplasms (IPMNs) may perforate into adjacent organs, but pancreaticobiliary fistula caused by IPMN is rare. We present a rare case of pancreaticobiliary fistula due to a branch-duct IPMN, accelerated by a simultaneous ampullary carcinoma. Patient concerns: A woman in her 70s developed obstructive jaundice and cholangitis after a year of follow-up for IPMN. Diagnoses: Imaging revealed a branch-duct IPMN with a mural nodule and dilation of the main pancreatic duct, along with a dilated distal bile duct. Perforation into the bile duct and lymphadenopathy were observed. Histopathology later confirmed a high-grade intestinal-type IPMN and an incidental ampullary ductal carcinoma. Interventions: The patient underwent endoscopic biliary drainage followed by pancreaticoduodenectomy after improvement of cholangitis. Outcomes: The postoperative course was favorable. The pancreaticobiliary fistula was attributed to mechanical compression by mucin-producing IPMN, complicated by ampullary carcinoma. Lessons: This case highlights the importance of recognizing synergistic effects of concurrent periampullary neoplasms. Surgical resection may be curative and necessary to control complex biliary obstruction and infection.

3 October 2023 in Surgical Case Reports
Verified
Journal Article
Open access
PDF file
HKHiroki Kushiya
Hiroki Kushiya
YAYoshiyasu Ambo
Yoshiyasu Ambo
MTMinoru Takada
Minoru Takada
TMTakahiko Masuda
Takahiko Masuda
SNShuichi Naraoka
Shuichi Naraoka
SHSatoshi Hirano
Satoshi Hirano
Background: The prognosis of hepatocellular carcinoma (HCC) with vascular invasion is extremely poor, especially in patients with tumor thrombus (TT) of the inferior vena cava (IVC), which is an oncological emergency with a high risk of sudden death due to TT extension or migration. Herein, we describe a case of HCC with TT of the IVC that rapidly extended into the right atrium (RA), in which right hepatectomy was performed under cardiopulmonary bypass. Case presentation: A 64-year-old man was diagnosed with HCC with IVC TT, and right hepatic lobectomy was scheduled. While awaiting surgery, he complained of respiratory distress and rushed to the emergency room. The TT had reached the RA, and the patient was in a state of oncologic emergency. We requested the cooperation of the cardiovascular surgery department, and under artificial cardiopulmonary support, the right atrium was incised, and a part of the TT was removed. The IVC was clamped to prevent tumor dispersal, and right hepatic lobectomy was performed. The remaining thrombus was excised along with the right lobe of the liver by incising the IVC. There were no serious postoperative complications, and the patient is alive 1 year and 5 months postoperatively. Conclusion: Hepatic resection with cardiopulmonary bypass could be an option for HCC with TT reaching the RA.

19 June 2023 in Trials
Verified
Journal Article
Open access
PDF file
NONaoya Okada
Naoya Okada
YKYoshihiro Kinoshita
Yoshihiro Kinoshita
SNShoji Nishihara
Shoji Nishihara
TKTakuma Kurotaki
Takuma Kurotaki
ASAya Sato
Aya Sato
FNFumitaka Nakamura
Fumitaka Nakamura
Background: After esophagectomy for esophageal and esophagogastric cancer, more than half of patients have lost > 10% of their body weight at 12 months. In most cases, the gastric remnant is used for reconstruction after esophagectomy. One of the most serious nutritional complications of this technique is delayed gastric emptying caused by gastric remnant mobilization and denervation of the vagus nerve. The aim of the PYloroplasty versus No Intervention in GAstric REmnant REconstruction after Oesophagectomy (PYNI-GAREREO) trial is to analyze the clinical outcome of modified Horsley pyloroplasty (mH-P) as a method of preventing delayed gastric emptying. Methods: The PYNI-GAREREO trial is designed as an open randomized, single-center superiority trial. Patients will be randomly allocated to undergo gastric remnant reconstruction with mH-P (intervention group) or no intervention (control group) in parallel groups. All patients with esophageal cancer or esophagogastric cancer planning to undergo curative minimally invasive esophagectomy will be considered for inclusion. A total of 140 patients will be included in the study and randomized between the groups in a 1:1 ratio. The primary outcome is the body weight change at 6 months postoperatively, and the secondary outcomes are the nutritional status, postoperative complications, functional outcome, and quality of life until 1 year postoperatively. Discussion: We hypothesize that mH-P after minimally invasive esophagectomy more effectively maintains patients’ nutritional status than no pyloroplasty. Trial registration: UMIN Clinical Trials Registry UMIN000045104. Registered on 25 August 2021. https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000051346.